Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer
To evaluate the safety of karillizumab combined with apatinib mesylate, XELOX and radiofrequency ablation
Hepatic Metastasis of Colorectal Cancer
DRUG: Camrelizumab|DRUG: Apatinib Mesylate|DRUG: Capecitabine|DRUG: Oxaliplatin|RADIATION: radiofrequency ablation
R0 resection rate, The surgical procedure was total or subtotal proctectomy and hepatectomy with 4 cycles after Conversion therapy, 6 months
Objective response rate, Objective response rate according to Response Evaluation Criteria in Solid Tumours(RECIST)1.1, 6 months|pathologic complete response, pathologic complete response (pCR), 6 months
To evaluate the safety of karillizumab combined with apatinib mesylate, XELOX and radiofrequency ablation.

The 23 patients were enrolled in a 3-week regimen with 200mg Camrelizumab given intravenously every 3weeks and 250mg apatinib mesylate qd ，and 850mg/m2 capecitabine d1-14 and 130mg/m2 oxaliplatin given intravenously d1.